The high cost and time required for US clinical trials create a rational economic incentive for companies and investors to move operations to China. The solution isn't to match China's low costs, but to significantly improve US efficiency to make domestic investment more competitive.

With a highly concentrated population, a single-payer system, and vast hospital capacity (90,000 beds in Seoul vs. 4,000 in Boston), South Korea offers a significant advantage for clinical development. This infrastructure allows trials to be completed 40% faster and at 40% lower cost compared to the US.

Eli Lilly's deal with Innovent outsources R&D through Phase 2 to China. This leverages China's faster clinical development environment, allowing Lilly to de-risk assets before committing to costly global trials, effectively creating an externalized early-stage pipeline.

US biotechs increasingly use sites like Australia to accelerate development, as Create Medicines did by moving from concept to clinic in under 12 months. What was once viewed with suspicion is now a key strategy to generate data faster and more cheaply, competing with the speed of China's ecosystem.

The US regulatory regime for early clinical trials is so slow that companies are opting for more efficient systems, like Australia's local IRB-based approval. This offshoring of initial research puts the US at a global competitive disadvantage in generating crucial early data.

The current unpredictability at the FDA is so pronounced that prominent biotech investor Peter Kolchinsky of RA Capital is now advising his portfolio companies to de-risk development by conducting early-stage clinical trials outside the United States. This marks a significant strategic shift for US-based innovators.

Through massive government investment in biotech infrastructure, China has become the global hub for early-stage clinical drug development. Both Chinese and Western companies now conduct initial human trials there to move much faster and at a significantly lower cost, giving China a strategic foothold in the pharma value chain.

The FDA now allows a single, well-designed pivotal trial instead of the traditional two. This reform significantly cuts costs by $100M-$300M and shortens development timelines, enabling companies to test twice as many potential drugs with the same capital.

U.S. FDA requirements for early-stage trials, particularly safety margins, are considered ill-suited for genetic medicines, prompting companies to look abroad. The UK is emerging as a preferred destination, with its regulator, the MHRA, actively creating incentives and faster pathways to attract these innovative clinical programs.